CAP-CMV GmbH Raises New Funds to Further Develop Its Novel HCMV Vaccine and Appoints New CEO

March 24, 2014 CAP-CMV GmbH, a company focusing exclusively on the development of a novel vaccine protecting against human Cytomegalovirus (hCMV) infection, announced today that it raised in total € 1.7 m from its investors Peppermint Venture Partners (PVP), NRW.Bank, Creathor Venture, KfW and private investors in a combined seed/start-up investment. The funds will be used to advance further it´s vaccine candidate, …